Title:
METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE-RELATED DISEASES OR DISORDERS AND/OR THERAPY MONITORING
Document Type and Number:
WIPO Patent Application WO/2015/143343
Kind Code:
A3
Abstract:
Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of TIGIT, Flg2 and/or IL-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of autoimmune diseases and/or inflammation (e.g., caused by parasitic infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of asthma, allergy, and/or atopy. Methods for identifying patients who are more likely to be responsive to and benefit from an immunotherapy that targets TIGIT, Fg12 and/or IL-33 are also described herein.
Inventors:
KUCHROO VIJAY (US)
JOLLER NICOLE (CH)
ANDERSON ANA C (US)
BURKETT PATRICK (US)
JOLLER NICOLE (CH)
ANDERSON ANA C (US)
BURKETT PATRICK (US)
Application Number:
PCT/US2015/021784
Publication Date:
March 24, 2016
Filing Date:
March 20, 2015
Export Citation:
Assignee:
BRIGHAM & WOMENS HOSPITAL (US)
International Classes:
C12Q1/68
Domestic Patent References:
| WO2012031008A2 | 2012-03-08 |
Foreign References:
| US20130251720A1 | 2013-09-26 | |||
| US20100298418A1 | 2010-11-25 | |||
| US20080003199A1 | 2008-01-03 | |||
| US20050169913A1 | 2005-08-04 |
Other References:
KHATTAR ET AL.: "Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE", PLOS ONE, vol. 8, 11 October 2013 (2013-10-11), pages 1 - 11, XP055358672
JOLLER ET AL.: "Immune checkpoints in central nervous system autoimmunity", IMMUNOL REV., vol. 248, 1 July 2012 (2012-07-01), pages 122 - 139, XP055145273
JOLLER ET AL.: "Cutting edge: TIGIT has T cell -intrinsic inhibitory functions", J IMMUNOL., vol. 186, 1 February 2011 (2011-02-01), pages 1338 - 1342, XP055319470
FOERSTER ET AL.: "The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection", J HEPATOL., vol. 53, 17 June 2010 (2010-06-17), pages 608 - 615, XP027241346
YU ET AL., NAT IMMUNOL., vol. 10, 16 November 2008 (2008-11-16), pages 48 - 57, XP055273979
JOLLER ET AL.: "Immune checkpoints in central nervous system autoimmunity", IMMUNOL REV., vol. 248, 1 July 2012 (2012-07-01), pages 122 - 139, XP055145273
JOLLER ET AL.: "Cutting edge: TIGIT has T cell -intrinsic inhibitory functions", J IMMUNOL., vol. 186, 1 February 2011 (2011-02-01), pages 1338 - 1342, XP055319470
FOERSTER ET AL.: "The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection", J HEPATOL., vol. 53, 17 June 2010 (2010-06-17), pages 608 - 615, XP027241346
YU ET AL., NAT IMMUNOL., vol. 10, 16 November 2008 (2008-11-16), pages 48 - 57, XP055273979
Attorney, Agent or Firm:
RESNICK, David S. et al. (100 Summer StreetBoston, Massachusetts, US)
Download PDF:
Previous Patent: PRODUCTION OF MIDBRAIN DOPAMINERGIC NEURONS AND METHODS FOR THE USE THEREOF
Next Patent: NASAL DILATOR
Next Patent: NASAL DILATOR